Schizophrenia

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.  “Vanderbilt is proud that a discovery by our researchers at the Warren Center… Read More

THE IDEA   Jeffrey Conn (John Russell/Vanderbilt University) James Maksymetz A new study led by Jeff Conn, Lee E. Limbird Chair in Pharmacology, James Maksymetz, a former graduate student in the Conn laboratory, and other collaborators at the Warren Center for… Read More

Around 500 million people around the world are affected by poor mental health including disorders such as depression, schizophrenia, bipolar disease and dementia with a significant impact on quality of life as well as associated social and economic consequences.1 Boehringer Ingelheim is dedicated to redefining the management of mental health. Read More